Clinical trial
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like…
NCT00125164 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00125164 |
|---|---|
| Title | Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency |
| Official title | Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Disorders, Insulin-Like Growth Factor-1 Deficiency |
| Intervention type | Drug |
| Interventions | rhIGF-1 (mecasermin, Tercica, Inc.) |
| Enrollment | 137 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jul 29, 2005 |
| Last update posted | Sep 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: